Am I Treatment Resistant, or Was the Depression Never Fully Treated?

You have a number in your head. Three medications. Or five. You can name them in order, when each started and why each stopped, and somewhere along the way a phrase attached itself to you: I’m treatment resistant.

It does not land like a description. It lands like a verdict.

“Am I treatment resistant?” is a question about the treatment so far, not about you.

If you are in crisis or thinking about harming yourself right now, call or text 988 to reach the Suicide & Crisis Lifeline, available 24/7, or go to your nearest emergency room. For non-urgent questions, our office is at 817-659-7344.

We already have a post on our blog explaining what treatment-resistant depression is. This is the sequel: the look backward that should happen before the label sets, and in our Fort Worth office that is where a re-evaluation starts.

Am I treatment resistant, or was something missed?

There is a word for the second possibility. In a 2023 review in World Psychiatry, McIntyre and colleagues write that “a significant percentage of persons with TRD are actually pseudo-resistant”: resistance that comes from inadequate trials, or medication not taken consistently.

Nobody has a trustworthy number for that share, but guidelines build the look-back in anyway. The VA/DoD guideline for major depressive disorder (2022) says a patient with partial or no response after an adequate trial “should be reassessed for possible diagnostic error, the presence of co-occurring conditions, and treatment adherence.”

Diagnosis, then comorbidity, then adherence. A wrong answer early makes every later one wrong. Roughly:

1. Is the diagnosis right?
2. Did each trial run long enough, at a dose your prescriber called fair?
3. Did a side effect end it early?
4. Was it taken consistently, and if not, what got in the way?
5. Is something else keeping it going: a medical condition, sleep, alcohol?

Is there an official number of failed antidepressants?

There is not. The Agency for Healthcare Research and Quality reported in 2018 that “no consensus definition existed for TRD,” and a 2022 consensus paper in Molecular Psychiatry reports a review that found 155 definitions, only 48.4 percent specifying at least two sequential failures.

Two failed trials is the most common research convention. If the experts cannot agree where the line sits, it is not a fact about you.

Is the diagnosis right?

Bipolar disorder that was never recognized

The National Institute of Mental Health notes that some people live with bipolar disorder for years before it is diagnosed, partly because people with bipolar II “may seek help only for depressive episodes, and hypomanic episodes may go unnoticed.”

And the diagnosis changes the treatment. NIMH states that in bipolar disorder, antidepressants “are not used alone because they can trigger a manic episode or rapid cycling.” The manic symptoms NIMH lists include feeling very up or unusually irritable, a decreased need for sleep, racing thoughts and a jump in activity. If you are taking an antidepressant and notice a stretch like that, tell your prescriber promptly rather than waiting for the next visit, and do not stop the medication on your own.

It is not rare in this group, either. A 2010 review in the Journal of Affective Disorders examined 196 articles and reported data suggesting that treatment-resistant populations “demonstrate high rates of hidden bipolar disorder,” and that in people who do have bipolar disorder, antidepressants “are not robustly effective and are poorly tolerated.” What matters is getting the diagnosis right, not changing anything on your own.

A questionnaire cannot settle it. The World Psychiatry review notes that screening tools “are not sufficient to diagnose bipolar disorder,” though a positive screen is reason for a fuller assessment. What does the work is a careful history, often with a family member’s account, which is what a bipolar disorder evaluation is for.

What counts as an adequate antidepressant trial?

Long enough to know, at a dose your prescriber considered fair.

The VA/DoD guideline works from a six-to-twelve-week benchmark, with a condition that matters: those weeks count only if the dose was advanced to the labeled maximum, or to what you could tolerate, and held there at least four to six weeks. Time at a starting dose is not the same as time at a trial dose. A 2011 American Family Physician summary of the APA guideline makes a related point: without moderate improvement in four to eight weeks, the diagnosis should be reconsidered.

The World Psychiatry review cites research in which roughly 20 percent of non-responders at four weeks responded in weeks five to eight, and roughly 10 percent in weeks nine to twelve. Late responses are real.

Dose does not run in one direction either. The VA/DoD guideline cautions that “maximizing the dose of an SSRI may not be clinically useful,” citing evidence of no clinically relevant dose-response gradient and more dropout at higher doses. Which kind of trial you had is a question for your prescriber.

When we build the timeline, we write down four things per medication: what it was, how long, what dose you reached, and why it stopped. That last column is usually where the explanation is.

You may also have met a percentage from STAR*D, the large NIMH-funded treatment study. We are leaving those figures out: the 2006 rates were challenged by a 2023 BMJ Open reanalysis, then defended by the original investigators.

Does a medication I stopped early still count as a failed trial?

A trial that ended in week two because of nausea tells you about tolerability. It tells you almost nothing about whether it would have helped. Collapsing the two is a quiet way a list of failures grows.

Adherence is the same question. The World Psychiatry review reports that about 30 to 50 percent of people prescribed antidepressants are non-adherent in acute-phase treatment, and a 2026 review in Frontiers in Pharmacology notes that adherence “is rarely formally assessed, despite being a major contributor to pseudo-resistance.”

None of that is anyone’s fault. Doses get missed because of side effects, cost, feeling better, feeling worse, a lapsed refill. We ask flatly, because almost nobody volunteers it: “how many days last month did you miss?” gets a truer answer than “are you taking it?”

What else could be keeping the depression going?

Sometimes a medication is working against something else.

A re-evaluation also asks directly about safety: whether you have had thoughts of suicide, now or in the past. In the VA/DoD guideline it sits in the same work-up sidebar as the medical causes below. It is routine, and easier to say than to carry alone.

That sidebar tells clinicians to rule out depression secondary to other causes, naming hypothyroidism, vitamin B-12 deficiency, pain and chronic disease. The National Institute of Diabetes and Digestive and Kidney Diseases lists depression among hypothyroidism’s symptoms, noting the diagnosis “can’t be based on symptoms alone.” Pain is on that list too, which is why chronic pain and mood are treated as one picture.

Sleep-disordered breathing belongs there too: a 2020 review in Maturitas found a higher risk of depression in people with sleep apnea followed over years, though no clear association at a single point in time. Diagnosing it takes a sleep study.

The National Institute on Alcohol Abuse and Alcoholism reports that alcohol dependence, particularly severe dependence, has been associated with depression persisting, and that antidepressants have only modest effects on drinking. The two are best addressed together, and cutting down or stopping is worth planning with a clinician: stopping abruptly after heavy drinking can be risky.

Trauma is often the one nobody asked about. The VA/DoD guideline names PTSD among the conditions that may worsen depression, and the Frontiers review says reassessment should exclude conditions that “may mimic or worsen depressive symptoms,” including complex PTSD and prolonged grief.

What a second opinion is actually for

A second opinion is a fresh reading of the record. Every clinician on your list worked with what was known at the time, and a re-evaluation is usually less about finding a mistake than about surfacing what was not on the table before. Sometimes it does change the diagnosis, which is why it is worth doing.

Bring what makes that possible: a pharmacy printout of what you were dispensed, records from prior prescribers, and anyone who remembers the stretches you do not.

Sometimes it confirms this has genuinely been resistant depression, and the conversation moves to treatment options for refractory depression. Either way, do not start, stop or change a psychiatric medication on your own, and never stop one abruptly.

Frequently asked questions

How many antidepressants before you are considered treatment resistant?
There is no official threshold. AHRQ reported in 2018 that no consensus definition existed, and that its most frequently used research definition required two prior failures with confirmed adequate dose and duration. A 2022 paper in Molecular Psychiatry reports a review that found 155 definitions, fewer than half specifying at least two sequential failures.

Nothing works for my depression. Does that mean nothing ever will?
Not necessarily, and the framing is worth challenging. The record usually shows a set of trials, each with a length, a dose, a tolerability story and a diagnosis behind it, and any of those can be revisited. A 2023 World Psychiatry review notes that much apparent resistance is pseudo-resistance. If hopelessness is heavy, call or text 988.

Could I have bipolar disorder instead?
It is worth a real evaluation. NIMH notes that hypomanic episodes often go unnoticed and that people with bipolar II may seek help only for depression, and a 2010 review in the Journal of Affective Disorders reported data suggesting high rates of unrecognized bipolar disorder in treatment-resistant populations. A careful history, not a questionnaire, is what settles it.

Should I get genetic testing to find the right antidepressant?
The evidence is limited. The VA/DoD guideline found insufficient evidence to recommend for or against pharmacogenetic testing, and the 2022 PRIME Care trial in JAMA, with 1,944 patients, found that testing changed prescribing but produced only small, non-lasting symptom differences and no significant difference in remission at 24 weeks. The FDA says it has not authorized any direct-to-consumer pharmacogenetic test that predicts response to a specific drug.

The bottom line

Treatment resistant describes what has been tried so far, not who you are. A careful re-evaluation works through those five questions in order, and some of what it turns up changes the plan while some does not. The VA/DoD guideline is honest that the search can be long, noting that in STAR*D “at least one-third of patients did not achieve remission after four consecutive, highly optimized treatment steps.” Even so, depression that has resisted several treatments is not the same as depression with nothing left to consider.

Talk with us

If you are in Fort Worth or the surrounding North Texas area and what you have read here sounds familiar, we would be glad to talk it through with you. The Institute for Advanced Psychiatry is an outpatient practice at 6800 Harris Parkway, Suite 100, treating adults 18 and older. You can request an appointment or call 817-659-7344.

If you are in crisis or thinking about harming yourself, please do not wait for an appointment. Call or text 988 to reach the Suicide & Crisis Lifeline, available 24/7, or go to your nearest emergency room.

Sources

1. Gaynes BN, Asher G, Gartlehner G, et al. “Definition of Treatment-Resistant Depression in the Medicare Population.” Agency for Healthcare Research and Quality. 2018. https://www.ncbi.nlm.nih.gov/books/NBK526366/
2. McIntyre RS, Alsuwaidan M, Baune BT, et al. “Treatment-resistant depression: definition, prevalence, detection, management, and investigational interventions.” World Psychiatry. 2023;22(3):394-412. https://pmc.ncbi.nlm.nih.gov/articles/PMC10503923/
3. Sforzini L, Worrell C, Kose M, et al. “A Delphi-method-based consensus guideline for definition of treatment-resistant depression for clinical trials.” Molecular Psychiatry. 2022. https://pmc.ncbi.nlm.nih.gov/articles/PMC9095475/
4. Paribello P, Isayeva U, Lazzardi S, et al. “The relevance of phenotypic definition in treatment resistant forms of major depressive disorder: a narrative review.” Frontiers in Pharmacology. 2026;17:1819237. https://pmc.ncbi.nlm.nih.gov/articles/PMC13299096/
5. U.S. Department of Veterans Affairs / U.S. Department of Defense. “VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder (Version 4.0).” 2022. https://www.healthquality.va.gov/guidelines/MH/mdd/VADODMDDCPGFinal508.pdf
6. Armstrong C. “APA Releases Guideline on Treatment of Patients with Major Depressive Disorder.” American Family Physician. 2011. https://www.aafp.org/pubs/afp/issues/2011/0515/p1219.html
7. National Institute of Mental Health. “Sequenced Treatment Alternatives to Relieve Depression (STAR*D).” Accessed 2026. https://www.nimh.nih.gov/funding/clinical-research/practical/stard
8. Rush AJ, Trivedi MH, Wisniewski SR, et al. “Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report.” American Journal of Psychiatry. 2006;163(11):1905-1917. https://europepmc.org/article/MED/17074942
9. Pigott HE, Kim T, Xu C, Kirsch I, Amsterdam J. “What are the treatment remission, response and extent of improvement rates after up to four trials of antidepressant therapies in real-world depressed patients? A reanalysis of the STAR*D study’s patient-level data with fidelity to the original research protocol.” BMJ Open. 2023;13(7):e063095. https://europepmc.org/article/MED/37491091
10. Rush AJ, Trivedi M, Fava M, Thase M, Wisniewski S. “The STAR*D Data Remain Strong: Reply to Pigott et al.” American Journal of Psychiatry. 2023;180(12):919-920. https://psychiatryonline.org/doi/10.1176/appi.ajp.20230869
11. National Institute of Mental Health. “Bipolar Disorder.” Last revised 2025. https://www.nimh.nih.gov/health/publications/bipolar-disorder
12. Correa R, Akiskal H, Gilmer W, Nierenberg AA, Trivedi M, Zisook S. “Is unrecognized bipolar disorder a frequent contributor to apparent treatment resistant depression?” Journal of Affective Disorders. 2010;127(1-3):10-18. https://europepmc.org/article/MED/20655113
13. Oslin DW, Lynch KG, Shih MC, et al. “Effect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder: The PRIME Care Randomized Clinical Trial.” JAMA. 2022;328(2):151-161. https://pmc.ncbi.nlm.nih.gov/articles/PMC9277497
14. U.S. Food and Drug Administration. “Direct-to-Consumer Tests (In Vitro Diagnostics).” Accessed 2026. https://www.fda.gov/medical-devices/in-vitro-diagnostics/direct-consumer-tests
15. National Institute of Diabetes and Digestive and Kidney Diseases. “Hypothyroidism (Underactive Thyroid).” Last reviewed March 2021. https://www.niddk.nih.gov/health-information/endocrine-diseases/hypothyroidism
16. Edwards C, Almeida OP, Ford AH. “Obstructive sleep apnea and depression: A systematic review and meta-analysis.” Maturitas. 2020;142:45-54. https://europepmc.org/article/MED/33158487
17. McHugh RK, Weiss RD. “Alcohol Use Disorder and Depressive Disorders.” Alcohol Research: Current Reviews (National Institute on Alcohol Abuse and Alcoholism). 2019;40(1). https://pmc.ncbi.nlm.nih.gov/articles/PMC6799954/

Medical disclaimer

This article is for general education and is not medical advice, a diagnosis, or a treatment recommendation for any individual. Reading it does not create a physician-patient relationship. Treatment decisions, including whether any medication or procedure is appropriate for you, should be made with a qualified clinician who knows your history. Do not start, stop, or change a psychiatric medication without talking to your prescriber. If you are experiencing a medical or mental health emergency, call 911 or 988.